Evidence map›Paper›PMID 36632983›Full record

Trial reportMultiple sclerosis (Houndmills, Basingstoke, England)2023

Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.

Jens Kuhle, Tanuja Chitnis, Brenda Banwell, Marc Tardieu, Douglas L Arnold, Andreea M Rawlings, Svend S Geertsen, Alex L Lublin, Stephane Saubadu, Philippe Truffinet and 1 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Multiple sclerosis (Houndmills, Basingstoke, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02201108 (A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02201108 phase3completednot on this map

A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension

TypeinterventionalSponsorGenzyme, a Sanofi CompanyRan2014 to 2024Enrolled166ConditionsMultiple SclerosisArmsTeriflunomide, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Jens KuhleMS Center, Neurology and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Biomedicine and Clinical Research, University Hospital Basel and University Basel, Basel, Switzerland.
Tanuja ChitnisMassachusetts General Hospital for Children, Boston, MA, USA.ORCID 0000-0002-9897-4422
Brenda BanwellChildren's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA.
Marc TardieuHôpitaux Universitaires Paris-Sud, Paris, France.
Douglas L ArnoldMcGill University, Montréal, QC, Canada NeuroRx Research, Montréal, QC, Canada.ORCID 0000-0003-4266-0106
Andreea M RawlingsSanofi, Cambridge, MA, USA.
Svend S GeertsenSanofi, Cambridge, MA, USA.
Alex L LublinSanofi, Cambridge, MA, USA.
Stephane SaubaduSanofi, Cambridge, MA, USA.
Philippe TruffinetSanofi, Cambridge, MA, USA.
Ludwig KapposMS Center, Neurology and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Biomedicine and Clinical Research, University Hospital Basel and University Basel, Basel, Switzerland.ORCID 0000-0003-4175-5509
Sanofi (United States) · USBoston Children's Hospital · USChildren's Hospital of Philadelphia · USHôpitaux Universitaires Paris-Ouest · FRNeuroRx Research (Canada) · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe phase 3 TERIKIDS study demonstrated efficacy and manageable safety for teriflunomide versus placebo in children with relapsing multiple sclerosis (RMS).

objectiveEvaluate plasma neurofilament light chain (pNfL) concentrations in TERIKIDS.

methodsPatients received placebo or teriflunomide (14 mg adult equivalent) for up to 96 weeks in the double-blind (DB) period. In the open-label extension (OLE), all patients received teriflunomide until up to 192 weeks after randomization. pNfL was measured using single-molecule array assay (Simoa

resultsBaseline mean age was 14.5 years; 69.4% were female. Baseline geometric least square mean pNfL levels were similar for teriflunomide (

conclusionTeriflunomide treatment was associated with significantly reduced pNfL levels in children with RMS. CLINICALTRIALS.GOV IDENTIFIER: NCT02201108.

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingAdolescentAdultChildCrotonatesFemaleHumansHydroxybutyratesIntermediate FilamentsMaleNitrilesToluidinesCrotonatesHydroxybutyratesNitrilesteriflunomideToluidinesNeurofilament light chainpediatric MSteriflunomide

Identifiers

PMID36632983
PMCPMC9972233
OpenAlexW4315699728

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.